Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

Launched by ERIKA MATOS · Oct 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how well patients with early-stage, hormone receptor-positive, HER2-negative breast cancer stick to their medication, particularly those taking a combination of aromatase inhibitors and a drug called abemaciclib. About 70% of breast cancer patients fall into this category, and even with treatments, some still face a risk of their cancer coming back. Researchers want to find out if patients taking both types of medication have a harder time following their treatment plan compared to those taking aromatase inhibitors alone. They believe factors like a patient’s quality of life, mental well-being, and previous treatment experiences may influence how consistently they take their medication.

To participate in this trial, women must be diagnosed with early-stage HR+/HER2- breast cancer and currently receiving treatment with an aromatase inhibitor for no more than 18 months. They should be able to communicate in Slovenian and provide consent to join the study. The trial is not yet recruiting, but if you qualify and choose to participate, you’ll help researchers understand how to improve treatment adherence, which is crucial for the effectiveness of breast cancer therapy.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female,
• • Early HR+/HER-2- BC,
• • Patient is receiving adjuvant therapy with an aromatase inhibitor (letrozole, anastrozole or exemestane), with or without a CDK4/6 inhibitor abemaciclib, for no more than 18 months,
• • Treatment of BC is being conducted at OIL,
• • Patient has mandatory health insurance through Health Insurance Institute of Slovenia,
• • Patient understands Slovenian language, and
• • Patient agrees to participate in the study and provides written informed consent.
• Exclusion Criteria:
• • Metastatic HR+/HER-2- BC
• • Previous treatment for BC with an aromatase inhibitor, with or without a CDK4/6 inhibitor, due to BC.